Cargando…

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression

Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ch, Saritha, Sudha, Sree, Reddy, C. Gowtham, T, Pugazhenthan, KSBS, Krishna Sasanka, Dasari, Pooja, Battula, Pradeep, T, Nandini, A, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971119/
https://www.ncbi.nlm.nih.gov/pubmed/35371643
http://dx.doi.org/10.7759/cureus.22717
_version_ 1784679578285899776
author Ch, Saritha
Sudha, Sree
Reddy, C. Gowtham
T, Pugazhenthan
KSBS, Krishna Sasanka
Dasari, Pooja
Battula, Pradeep
T, Nandini
A, Sandeep
author_facet Ch, Saritha
Sudha, Sree
Reddy, C. Gowtham
T, Pugazhenthan
KSBS, Krishna Sasanka
Dasari, Pooja
Battula, Pradeep
T, Nandini
A, Sandeep
author_sort Ch, Saritha
collection PubMed
description Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression. Methodology The patients who were diagnosed with depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria were included in the study and were divided into two groups. The severity of depression in these patients was evaluated using Beck Depression Inventory and Hamilton depression scale (HAM-D) before and after the treatment (four weeks). Results About 64% of the study sample were males, and 36% were females, with 77% of the patients in the desvenlafaxine group taking 100 mg dosage and about 74% patients taking 50 mg dosage in the sertraline group. The patients in both groups showed statistically significant (p < 0.00001) improvement after using these drugs. Conclusion Both desvenlafaxine and sertraline showed their efficacy in treating depression by improving the clinical outcome in patients. Sertraline was marginally better in clinical results. Finally, it is advisable to carry out more randomized trials to improve the patient’s quality of life.
format Online
Article
Text
id pubmed-8971119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89711192022-04-01 A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression Ch, Saritha Sudha, Sree Reddy, C. Gowtham T, Pugazhenthan KSBS, Krishna Sasanka Dasari, Pooja Battula, Pradeep T, Nandini A, Sandeep Cureus Neurology Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression. Methodology The patients who were diagnosed with depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria were included in the study and were divided into two groups. The severity of depression in these patients was evaluated using Beck Depression Inventory and Hamilton depression scale (HAM-D) before and after the treatment (four weeks). Results About 64% of the study sample were males, and 36% were females, with 77% of the patients in the desvenlafaxine group taking 100 mg dosage and about 74% patients taking 50 mg dosage in the sertraline group. The patients in both groups showed statistically significant (p < 0.00001) improvement after using these drugs. Conclusion Both desvenlafaxine and sertraline showed their efficacy in treating depression by improving the clinical outcome in patients. Sertraline was marginally better in clinical results. Finally, it is advisable to carry out more randomized trials to improve the patient’s quality of life. Cureus 2022-02-28 /pmc/articles/PMC8971119/ /pubmed/35371643 http://dx.doi.org/10.7759/cureus.22717 Text en Copyright © 2022, Ch et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Ch, Saritha
Sudha, Sree
Reddy, C. Gowtham
T, Pugazhenthan
KSBS, Krishna Sasanka
Dasari, Pooja
Battula, Pradeep
T, Nandini
A, Sandeep
A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
title A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
title_full A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
title_fullStr A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
title_full_unstemmed A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
title_short A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
title_sort comparative study on safety and efficacy of desvenlafaxine versus sertraline in depression
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971119/
https://www.ncbi.nlm.nih.gov/pubmed/35371643
http://dx.doi.org/10.7759/cureus.22717
work_keys_str_mv AT chsaritha acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT sudhasree acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT reddycgowtham acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT tpugazhenthan acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT ksbskrishnasasanka acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT dasaripooja acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT battulapradeep acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT tnandini acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT asandeep acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT chsaritha comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT sudhasree comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT reddycgowtham comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT tpugazhenthan comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT ksbskrishnasasanka comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT dasaripooja comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT battulapradeep comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT tnandini comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression
AT asandeep comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression